Intracellular delivery of cysteine protease inhibitor cystatin by polymeric nanoparticles

Journal of Nanoscience and Nanotechnology

Volumn 6, Issue 9-10, 2006, Pages 3087-3094

  Cegnar, Mateja ^a   Kos, Janko ^a   Kristl, Julijana ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cancer; Chitosan; Intracellular Targeting; Invasion; Nanoparticles; PLGA; Proteolysis

Indexed keywords

CHITOSAN; CYSTEINE PROTEASE; FLUORESCENCE MICROSCOPY; INTRACELLULAR TARGETING; PROTEOLYSIS;

COPOLYMERS; ENZYME INHIBITION; ENZYMES; FLUORESCENCE; GELATION; MICROSCOPIC EXAMINATION; NANOSTRUCTURED MATERIALS; ONCOLOGY; PRECIPITATION (CHEMICAL); TUMORS;

CONTROLLED DRUG DELIVERY;

CHITOSAN; CYSTATIN; DRUG CARRIER; LACTIC ACID; NANOMATERIAL; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; POLYMER; PROTEINASE INHIBITOR;

ARTICLE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; HUMAN; INTRACELLULAR FLUID; MATERIALS TESTING; METABOLISM; NEOPLASM; PARTICLE SIZE; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

CELL LINE, TUMOR; CELL SURVIVAL; CHITOSAN; CYSTATINS; DRUG CARRIERS; HUMANS; INTRACELLULAR FLUID; LACTIC ACID; MATERIALS TESTING; NANOSTRUCTURES; NEOPLASMS; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; PROTEASE INHIBITORS;

EID: 33750091937     PISSN: 15334880     EISSN: None     Source Type: Journal    
DOI: 10.1166/jnn.2006.401     Document Type: Conference Paper

References (46)

1. I. R. Hart, in Cellular and Molecular Biology of Cancer, edited by L. M. Franks and N. M. Teich, Imperial Cancer Research Fund, London, Oxford university press, New York (1997), p. 21.
2. P. Elvin and A. P. Garner, Curr. Opin. Pharmacol 5, 374 (2005).
3. J. Kos and T. Lan, Oncol. Report. 5, 1349 (1998).
4. G. J. Kim and S. Nie, Mater. Today 8, 28 (2005).
5. M. Cegnar, J. Kristl, and J. Kos, Expert Opin. Biol. Ther. 5, 1557 (2005).
6. K. J. Whittlesey and L. D. Shea, Exp. Neurol. 190, 1 (2004).
7. S. K. Sahoo and V. Labhasetwar, Drug Discov. Today 8, 1112 (2003).
8. P. M. Bummer and S. Koppenol, in Protein Formulation and Delivery, edited by E. J. McNally, Marcel Dekker, New York-Basel (2000), p. 5.
9. J. Kristl, J. Šmid-Korbar, E. Štruc, M. V. Schara, and H. Rupprecht, Int. J. Pharm. 99, 13 (1993).
10. D. Le Garrec, S. Gori, D. Karkan, L. Luo, D. G. Lessard, D. Smith, M. Ranger, M.-A. Yessine, and J.-C. Leroux, J. Drug Del. Sci. Tech. 15, 115 (2005).
11. Z. P. Xu, Q. H. Zeng, G. Q. Lu, and A. B. Yu, Chem. Engin. Sci. 61, 1027 (2006).
12. A. Premzl, V. Puizdar, V. Zavašnik-Bergant, N. Kopitar-Jerala, T. T. Lah, N. Katunuma, B. F. Sloane, V. Turk, and J. Kos, Biol. Chem. 382, 853 (2001).
13. J. Kos, M. Dolinar, and V. Turk, Agents Action. Supp. 38, 331 (1992).
14. P. Calvo, C. Remuñan-Lopez, J. L. Vila-Jato, and M. J. Alonso, Pharm. Res. 14, 1431 (1997).
15. M. Huang, E. Khor, and L. Y. Lim, Pharm. Res. 21, 344 (2004).
16. M. Cegnar, J. Kos, and J. Kristl, Eur. J. Pharm. Sci. 22, 357 (2004).
17. C. Holst-Hansen and N. Brünner, in Cell Biology: A Laboratory Handbook, edited by J. E. Celio, Academic press, San Diego (1998).
18. A. Premzl, V. Zavašnik-Bergant, V. Turk, and J. Kos, Exp. Cell Res. 283, 206 (2003).
19. C. Van Noorden, T. G. N. Jonges, J. Van Marie, E. R. Bissell, P. Griffini, M. Jans, J. Snel, and R. E. Smith, Clin. Exp. Metastasis. 16, 159 (1998).
20. T. Lopez-Leon, E. L. S. Carvalho, B. Seijo, J. L. Ortega-Vinuesa, and D. Bastos-Gonzales, J. Colloid. Interface. Sci. 283, 244 (2005).
21. S. A. Agnihotri, N. N. Mallikarjuna, and T. M. Aminabhavi, J. Control Rel. 100, 5 (2004).
22. M. Cegnar, A. Premzl, V. Zavašnik-Bergant, J. Kristl, and J. Kos, Exp. Cell Res. 301, 223 (2004).
23. G. Walsh, Eur. J. Pharm. Biopharm. 55, 3 (2003).
24. J. L. Cleland, A. Daugherty, and R. Mrsny, Curr. Opin. Biotechnol. 12, 212 (2001).
25. Y. Kawashima, Adv. Drug Del. Rev. 47, 1 (2001).
26. M. L. Hans and A. M. Lowman, Curr. Opin. Solid State Mater. Sci. 6, 319 (2002).
27. I. Brigger, C. Duberner, and P. Couvreur, Adv. Drug Del. Rev. 54, 631 (2002).
28. J. Panyam and V. Labhasetwar, Adv. Drug Del. Rev. 55, 329 (2003).
29. H. Maeda and Y. Matsumura, Crit. Rev. Ther. Drug Carrier Syst. 6, 193 (1989).
30. J. A. Bontempo, in Drug Delivery Principles and Applications, edited by B. Wang, T. Siahaan, and R. A. Soltero, John Wiley and Sons, Inc., Hoboken, New Jersey (2005), p. 321.
31. K. A. Janes, P. Calvo, and M. J. Alonso, Adv. Drug Del. Rev. 47, 83 (2001).
32. K. A. Janes, M. P. Fresneau, A. Marazuela, A. Fabra, and M. J. Alonso, J. Control. Rel. 73, 255 (2001).
33. K. A. Athanasiou, G. G. Niederauer, and C. M. Agrawal, Biomater. 17, 93 (1996).
34. J. M. Anderson and M. S. Shive, Adv. Drug Del. Rev. 28, 5 (1997).
35. A. A. Ignatius and L. E. Claes, Biomater. 17, 831 (1996).
36. C. T. Hanks, J. C. Wataha, and Z. Sun, Dent. Mater. 12, 186 (1996).
37. E. Cenni, G. Ciapetti, D. Granchi, C. R. Arciola, L. Savarino, S. Stea, L. Montanaro, and A. Pizzoferrato, Toxicol. In Vitro 13, 801 (1999).
38. S. Maassen, E. Fattal, R. H. Muller, and P. Couvreur, Pharm. Sci. 3, 11 (1993).
39. H. Yin, H. P. Too, and G. M. Chow, Biomater. 26, 5818 (2005).
40. S. Mitra, U. Gaur, P. C. Gosh, and A. N. Maitra, J. Control. Rel. 74, 317 (2001).
41. A. Smith and I. M. Hunneyball, Int. J. Pharm. 30, 215 (1986).
42. J. Davda and V. Labhasetwar, Int. J. Pharm. 233, 51 (2002).
43. J. S. Chawla and M. M. Amiji, AAPS Pharm. Sci. 5, 28 (2003).
44. C. Fonseca, S. Simoes, and R. Gaspar, J. Control. Rel. 83, 273 (2002).
45. C. Lemarchand, R. Gref, C. Passirani, E. Garcion, B. Petri, R. Muller, D. Costantini, and P. Couvreur, Biomater. 27, 108 (2006).
46. M. Sameni, K. Moin, and B. F. Sloane, Neoplasia 2, 496 (2000).